Compass Pathways Shares Surge 31% After Phase III TRD Trial Delivers 3.8-Point MADRS Drop
Compass Pathways jumped 31% after its COMP360 Phase III TRD trial (COMP006) yielded a 3.8-point MADRS reduction at 25mg versus 1mg control. Pooled COMP005 and COMP006 results showed 39% of patients achieved ≥25% MADRS decrease at week six and 25% maintained response through 26 weeks with minimal severe adverse events.
1. Phase III Trial Success
Compass Pathways’ COMP006 study achieved its primary endpoint by demonstrating a statistically significant 3.8-point reduction in MADRS scores for patients receiving two 25mg doses of COMP360 compared with a 1mg control.
2. Durability of Response
The ongoing COMP005 study revealed that 25% of patients in the 25mg cohort maintained clinically meaningful MADRS reductions through 26 weeks following one or two doses, underscoring the long-term efficacy of COMP360.
3. Safety Profile
Both Phase III trials reported low rates of severe treatment-emergent adverse events, with 5% in COMP005 and 2% in COMP006, and the most common side effects were headache, nausea, anxiety and visual hallucinations.
4. Market Reaction and Regulatory Outlook
The positive trial outcomes drove Compass Pathways’ stock from $5.81 on February 13 to $7.63 on February 17, a 31% gain, and the company plans to submit a new drug application for COMP360 in Q4 2026 aiming for commercial readiness by year-end.